At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 55 enrolled
Drug / intervention
lonafarnib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Dose-ranging, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Lonafarnib With Ritonavir-Boosting +/- Peginterferon Alfa-2a in Patients Chronically Infected With Delta Hepatitis (HDV) (LOWR-2)
In Brief
A Phase 2 clinical trial evaluating lonafarnib, ritonavir, and 1 other intervention for Chronic Hepatitis D Infection. Completed, enrolled 55 participants across 1 site.
Detailed Summary
An Open-label, Dose-ranging Study to Evaluate the Safety and Efficacy of Lonafarnib with Ritonavir Boosting +/- Peginterferon alfa-2a in Patients Chronically Infected with Delta Hepatitis (HDV) (LOWR-2).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis D Infection
CountriesTurkey (Türkiye)
CollaboratorsAnkara University
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartDec 2014
First PostedApr 2015
Primary CompletionApr 2017
Study CompletionJun 2017
TodayJul 2026
First PostedApr 30, 2015
Enrollment StartDec 1, 2014
Primary CompletionApr 18, 2017
Study CompletionJun 15, 2017
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 11.2 years ago
Interventions
lonafarnibdrug
antiviral farnesyl transferase inhibitor
ritonavirdrug
CYP 3A4 inhibitor, lonafarnib booster
Pegylated interferon-alfa-2adrug
immunomodulator